Comparison of Effects of Gliclazide, Metformin and Pioglitazone Monotherapies on Glycemic Control and Cardiovascular Risk Factors in Patients with Newly Diagnosed Uncontrolled Type 2 Diabetes Mellitus

Abstract

Objective: The objective of this study was to evaluate and compare the effects of gliclazide-modified release (gliclazide-MR), metformine (MET) and pioglitazone (PIO) monotherapies on glycemic control and conventional/non-conventional cardiovascular risk factors in patients with newly diagnosed type 2 diabetes mellitus (T2DM).

Material and Methods: A single center, randomized, 52-wk comparator-controlled clinical study was carried out in patients with newly diagnosed uncontrolled T2DM. A total of 57 patients were randomized into gliclazide-MR, metformin and pioglitazone groups. Drugs were administered for 12 months. Anthropometric measurements, fasting plasma glucose (FPG), postprandial plasma glucose (PPG), HbA1c, insulin, HOMA-IR, lipid parameters, the markers of coagulation/fibrinolysis, inflammation and endothelial dysfunction were measured at baseline and at months 3, 6, and 12.

Results: In the gliclazide-MR group, HC, FPG, HbA1c, insulin, HOMA-IR, TC, trigylcerides, Lp (a), E-selectin and Hcy were significantly decreased after treatment compared to baseline. In the MET group, BMI, WC, FPG, PPG, HbA1c, ICAM-1 and Hcy significantly decreased after treatment compared to baseline. In PIO group, WC, HC, FPG, PPG, HbA1c, C-peptid, HOMA-IR, trigylcerides, vWF, IL-6, ICAM-1, E-selectin and Hcy significantly decreased after treatment compared to baseline, whereas, HDL-C increased. At the end of the month 12, the decreases in insulin and HOMA-IR score were more pronounced with PIO compared to gliclazide.

Conclusions: Gliclazide-MR, MET and PIO monotherapies, were equally effective in proving glycemic control in patients with newly diagnosed, oral antidiabetic (OAD)-naive T2DM. But, improvements in conventional/non-conventional cardiovascular risk factors were more pronounced in patients on PIO therapy compared to gliclazide and MET therapies. Also, all of the 3 drugs represent effective and safe first-line pharmacological treatment options in these patients.

Key words

gliclazide-MR - metformin - pioglitazone - type 2 diabetes - cardiovascular risk factors - glycemic control

^* The Trabzon Endocrinological Studies Group, Trabzon, Turkey

• References

• 1 Haffner SM, Greenberg AS, Weston WM et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106: 679-684
• 2 Lund SS, Tarnow L, Stehouwer CD et al. Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes. Eur J Endocrinol 2008; 158: 631-641
• 3 Fidan E, Onder Ersoz H, Yilmaz M et al. The effects of rosiglitazone and metformin on inflammation and endothelial dysfunction in patients with type 2 diabetes mellitus. Acta Diabetol 2011; 48: 297-302
• 4 Erem C, Hacihasanoğlu A, Celik S et al. Coagulation and fibrinolysis parameters in type 2 diabetic patients with and without diabetic vascular complications. Med Princ Pract 2005; 14: 22-30
• 5 Pavo I, Jermendy G, Varkonyi TT et al. Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. The Journal of Clinical Endocrinology & Metabolism 2003; 88: 1637-1645
• 6 Vilar L, Canadas V, Arruda MJ et al. Comparison of metformin, gliclazide MR and rosiglitazone in monotherapy and in combination for type 2 diabetes. Arq Bras Endocrinol Metabol 2010; 54: 311-318
• 7 Levetan C. Oral antidiabetic agents in type 2 diabetes. Curr Med Res Opin 2007; 23: 945-952
• 8 Drouin P, Standl E. Diamicron MR Study Group . Gliclazide modified release: results of a 2-year study in patients with type 2 diabetes. Diabetes Obes Metab 2004; 6: 414-421
• 9 Khanolkar MP, Morris RH, Thomas AW et al. Rosiglitazone produces a greater reduction in circulating platelet activity compared with gliclazide in patients with type 2 diabetes mellitus – an effect probably mediated by direct platelet PPARgamma activation. Atherosclerosis 2008; 197: 718-724
• 10 Kim HJ, Kang ES, Kim DJ et al. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus. Clin Endocrinol (Oxf) 2007; 66: 282-289
• 11 Matthews DR, Charbonnel BH, Hanefeld M et al. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes Metab Res Rev 2005; 21: 167-174
• 12 Betteridge DJ, Vergès B. Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes. Diabetologia 2005; 48: 2477-2481
• 13 Tan MH. Current treatment of insulin resistance in type 2 diabetes mellitus. Int J Clin Pract Suppl 2000; 54-62
• 14 American Diabetes Association . Diagnosis and classification of diabetes mellitus. Diabetes Care 2010; 33 (Suppl. 01) S62-S69
• 15 Taniguchi A, Fukushima M, Sakai M et al. Remnant-like particle cholesterol, triglycerides, and insulin resistance in nonobese Japanese type 2 diabetic patients. Diabetes Care 2000; 23: 1766-1769
• 16 McAuley KA, Williams SM, Mann JI et al. Diagnosing insulin resistance in the general population. Diabetes Care 2001; 24: 460-464
• 17 Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502
• 18 Rodbard HW, Blonde L, Braithwaite SS et al. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007; 13 (Suppl. 01) 1-68
• 19 Yener S, Comlekci A, Akinci B et al. Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone. Medical Principles and Practice 2009; 18: 266-271
• 20 Belcher L, Lambert C, Edwards G et al. Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes. Diabetes Research and Clinical Practice 2005; 70: 53-62
• 21 Derosa G, Cicero AF, Gaddi A et al. A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. Diabetes Res Clin Pract 2005; 69: 5-13
• 22 Kahn SE, Haffner SM, Heise MA et al. ADOPT Study Group . Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443
• 23 Hanefeld M. Pioglitazone and sulfonylureas: effectively treating type 2 diabetes. Int J Clin Pract Suppl 2007; 61 (Suppl. 153) 20-27
• 24 Tan MH, Baksi A, Krahulec B et al. GLAL Study Group . Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes. Diabetes Care 2005; 28: 544-550
• 25 Perriello G, Pampanelli S, Di Pietro C et al. Italian Pioglitazone Study Group . Comparison of glycaemic control over 1 year with pioglitazone or gliclazide in patients with Type 2 diabetes. Diabet Med 2006; 23: 246-252
• 26 Kato T, Sawai Y, Kanayama H et al. Comparative study of low-dose pioglitazone or metformin treatment in Japanese diabetic patients with metabolic syndrome. Exp Clin Endocrinol Diabetes 2009; 117: 593-599
• 27 Charbonnel BH, Matthews DR, Schernthaner G et al. QUARTET Study Group . A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial. Diabet Med 2005; 22: 399-405
• 28 Fukuzawa M, Satoh J, Qiang X et al. Inhibition of tumor necrosis factor-alpha with anti-diabetic agents. Diabetes Res Clin Pract 1999; 43: 147-154
• 29 Cathelineau G, de Champvallins M, Bouallouche A et al. Management of newly diagnosed non-insulin-dependent diabetes mellitus in the primary care setting: effects of 2 years of gliclazide treatment – the Diadem Study. Metabolism 1997; 46 (Suppl. 01) 31-34
• 30 Chen KW, Juang JH, Huang HS et al. Effect of gliclazide on plasma lipids and pancreatic beta cell function in non-insulin-dependent diabetes mellitus. Changgeng Yi Xue Za Zhi 1993; 16: 246-250
• 31 Scarpello JH, Howlett HC. Metformin therapy and clinical uses. Diab Vasc Dis Res 2008; 5: 157-167
• 32 Perez A, Khan M, Johnson T et al. Pioglitazone plus a sulphonylurea or metformin is associated with increased lipoprotein particle size in patients with type 2 diabetes. Diab Vasc Dis Res 2004; 1: 44-50
• 33 Spanheimer R, Betteridge DJ, Tan MH et al. PROactive Investigators . Long-term lipid effects of pioglitazone by baseline anti-hyperglycemia medication therapy and statin use from the PROactive experience (PROactive 14). Am J Cardiol 2009; 104: 234-239
• 34 Tessier D, Maheux P, Khalil A et al. Effects of gliclazide versus metformin on the clinical profile and lipid peroxidation markers in type 2 diabetes. Metabolism 1999; 48: 897-903
• 35 Kassem SA, Raz I. Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity or mortality?. No. Diabetes Care 2009; 32 (Suppl. 02) S337-S341
• 36 Drzewoski J, Zurawska-Klis M. Effect of gliclazide modified release on adiponectin, interleukin-6, and tumor necrosis factor-alpha plasma levels in individuals with type 2 diabetes mellitus. Current Medical Research and Opinion 2006; 22: 1921-1926
• 37 De Jager J, Kooy A, Lehert P et al. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J Intern Med 2005; 257: 100-109
• 38 You SH, Kim BS, Hong SJ et al. The effects of pioglitazone in reducing atherosclerosis progression and neointima volume in type 2 diabetic patients: prospective randomized study with volumetric intravascular ultrasonography analysis. Korean Circ J 2010; 40: 625-631
• 39 Sacks HS, Fain JN, Cheema P et al. Inflammatory genes in epicardial fat contiguous with coronary atherosclerosis in the metabolic syndrome and type 2 diabetes: changes associated with pioglitazone. Diabetes Care 2011; 34: 730-733
• 40 Albertini JP, McMorn SO, Chen H et al. Effect of rosiglitazone on factors related to endothelial dysfunction in patients with type 2 diabetes mellitus. Atherosclerosis 2007; 195: e159-e166
• 41 Itoh M, Omi H, Okouchi M et al. The mechanisms of inhibitory actions of gliclazide on neutrophils-endothelial cells adhesion and surface expression of endothelial adhesion molecules mediated by a high glucose concentration. J Diabetes Complications 2003; 17: 22-26
• 42 Räkel A, Renier G, Roussin A et al. Beneficial effects of gliclazide modified release compared with glibenclamide on endothelial activation and low-grade inflammation in patients with type 2 diabetes. Diabetes Obes Metab 2007; 9: 127-129
• 43 Derosa G, Cicero AF, D’Angelo A et al. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial. Clin Ther 2006; 28: 679-688
• 44 Ryan KE, McCance DR, Powell L et al. Fenofibrate and pioglitazone improve endothelial function and reduce arterial stiffness in obese glucose tolerant men. Atherosclerosis 2007; 194: e123-e130
• 45 Schöndorf T, Musholt PB, Hohberg C et al. The fixed combination of pioglitazone and metformin improves biomarkers of platelet function and chronic inflammation in type 2 diabetes patients: results from the PIOfix study. J Diabetes Sci Technol 2011; 5: 426-432
• 46 Sahin M, Tutuncu NB, Ertugrul D et al. Effects of metformin or rosiglitazone on serum concentrations of homocysteine, folate, and vitamin B12 in patients with type 2 diabetes mellitus. J Diabetes Complications 2007; 21: 118-123
• 47 Derosa G, D'Angelo A, Ragonesi PD et al. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome. J Clin Pharm Ther 2006; 31: 375-383
• 48 Munshi MN, Stone A, Fink L et al. Hyperhomocysteinemia following a methionine load in patients with non-insulin-dependent diabetes mellitus and macrovascular disease. Metabolism 1996; 45: 133-135